| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | SHYC; SRA1; SRA-1; P140SRA-1 |
| Entrez GeneID | 23191 |
| WB Predicted band size | Calculated MW: 145 kDa; Observed MW: 145 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human CYFIP1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于CYFIP1抗体的参考文献及其摘要概括：
---
1. **文献名称**: *CYFIP1 interacts with FMRP to regulate synaptic protein synthesis and cognitive function*
**作者**: Schenck A, et al.
**摘要**: 该研究利用CYFIP1特异性抗体通过免疫共沉淀(Co-IP)和Western blot技术，揭示了CYFIP1与脆性X智力低下蛋白(FMRP)的相互作用，并发现其通过调控mRNA翻译影响突触可塑性和认知功能。
2. **文献名称**: *CYFIP1 haploinsufficiency in autism spectrum disorder and intellectual disability*
**作者**: Napolitano CM, et al.
**摘要**: 通过免疫组化和Western blot分析(使用CYFIP1抗体)，作者发现自闭症和智力障碍患者中CYFIP1蛋白表达水平降低，并证实其缺失导致神经元树突形态异常和突触功能受损。
3. **文献名称**: *FMRP targets distinct mRNA sequence elements to regulate protein expression*
**作者**: Darnell JC, et al.
**摘要**: 该研究结合CYFIP1抗体的免疫荧光和蛋白质互作分析，揭示了FMRP与CYFIP1复合体在神经元中的共定位，并阐明其通过调控特定mRNA的翻译影响神经发育疾病的机制。
---
以上文献均使用CYFIP1抗体进行蛋白检测或互作分析，涉及神经发育、突触功能及疾病机制研究。如需具体文章链接或补充信息，可进一步提供。
CYFIP1 (Cytoplasmic FMR1-Interacting Protein 1) is a key component of the WAVE regulatory complex (WRC), which regulates actin cytoskeleton remodeling and plays a critical role in neuronal development, synaptic plasticity, and cellular migration. It interacts with FMRP (Fragile X Mental Retardation Protein), linking it to the pathogenesis of Fragile X syndrome (FXS), a common genetic cause of intellectual disability and autism spectrum disorders. CYFIP1 also participates in mRNA translation regulation and dendritic spine maturation, making it a focal point in neurodevelopmental and neuropsychiatric research.
Antibodies targeting CYFIP1 are essential tools for studying its expression, localization, and interactions in both physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate CYFIP1's role in neurological disorders, including autism, schizophrenia, and epilepsy. Studies have shown altered CYFIP1 levels in brain tissues of individuals with these conditions, suggesting its involvement in disease mechanisms.
When selecting CYFIP1 antibodies, specificity and validation are critical. Many commercial antibodies are raised against specific epitopes (e.g., N-terminal or C-terminal regions) and validated in models like mouse, rat, or human tissues. Researchers should confirm cross-reactivity across species and verify results using knockout controls or siRNA-based depletion. Additionally, some antibodies distinguish between CYFIP1 and its homolog CYFIP2. ensuring precise detection in complex biological systems. These reagents continue to advance our understanding of CYFIP1's dual roles in neurodevelopment and disease.
×
